'Three-Person IVF' Technique Moves Closer
By BBC,
BBC News
| 01. 19. 2012
It replaces defective genetic material in the egg in order to eliminate rare mitochondrial diseases.
After the consultation into "three-person IVF", ministers will decide whether to allow it in patients.
A £5.8m centre at Newcastle University, funded by the Wellcome Trust, will investigate the technique's safety.
Inherited defects
Mitochondria can be found within almost every human cell, and provide the energy they need to function.
Like the nucleus of the cell, they contain DNA, although in tiny quantities.
Approximately 1 in 5,000 babies is born with inherited defects in their mitochondrial DNA, the effects of which can be very severe, or even fatal, depending on which cells are affected.
Scientists believe they have found a way to substitute the defective mitochondria and hopefully prevent the child from developing a disease.
They take two eggs, one from the mother and another from a donor.
The nucleus of the donor egg is removed, leaving the rest of the egg contents, including the mitochondria, and is replaced with the nucleus from the mother's egg.
The resulting embryo has properly functioning mitochondria from the...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...